Compare VRTX & HOOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | HOOD |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 105.6B |
| IPO Year | 1991 | 2021 |
| Metric | VRTX | HOOD |
|---|---|---|
| Price | $459.29 | $117.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 24 |
| Target Price | ★ $501.42 | $120.59 |
| AVG Volume (30 Days) | 1.3M | ★ 21.8M |
| Earning Date | 02-09-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 304.26 |
| EPS | ★ 14.22 | 2.39 |
| Revenue | ★ $11,723,300,000.00 | $4,204,000,000.00 |
| Revenue This Year | $11.01 | $54.96 |
| Revenue Next Year | $8.74 | $23.18 |
| P/E Ratio | ★ $32.61 | $48.21 |
| Revenue Growth | 10.33 | ★ 74.58 |
| 52 Week Low | $362.50 | $29.66 |
| 52 Week High | $519.68 | $153.86 |
| Indicator | VRTX | HOOD |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 46.97 |
| Support Level | $443.12 | $113.87 |
| Resistance Level | $487.52 | $124.35 |
| Average True Range (ATR) | 9.35 | 3.97 |
| MACD | -0.29 | 0.12 |
| Stochastic Oscillator | 36.42 | 52.93 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.